Indeed, in bRAF (b-RAF proto-oncogene)-driven melanomas, JNK-cJun (cellular-Jun proto-oncogene) signalling has been revealed to contribute to tumour progression, suggesting that blocking JNK signalling may be of therapeutic benefit in at least some cancer types [124,125,126]. This evidence concerns the gene JUN and neoplasm.